Eli Lilly and Company has emerged as in the production of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant potential to improve glycemic control and reduce cardiovascular risks. The complex manufacturing process of tirzepatide utilizes a series of precision steps